Navigation Links
$1.4 million grant awarded to study 2 little-understood neurological disorders
Date:12/18/2007

NEW YORK (Dec. 17, 2007) -- The Leon Levy Foundation has awarded over $1.4 million in grants to NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City in support of collaborative research into two little-understood neurological disorders: chemotherapy-related cognitive dysfunction in adult cancer patients and Normal Pressure Hydrocephalus (NPH), also known as "water on the brain," a progressive neurologic disorder in older adults that may be present in as many as 5 percent of dementia cases.

The three-year joint study on chemotherapy-related cognitive dysfunction will assess changes in brain structure, particularly in the hippocampus and the white matter, and cognitive functions in adult cancer patients treated with chemotherapy prior to receiving a stem-cell transplant.

"A significant number of cancer patients treated with chemotherapy experience changes in memory and other cognitive functions that interfere with their ability to lead a normal life. Yet despite the seriousness of the problem, little is known about it," says the study's principal investigator, Dr. Denise D. Correa, assistant professor of neuropsychology in Neurology at Weill Cornell Medical College and a neuropsychologist at NewYork-Presbyterian/Weill Cornell and at Memorial Sloan-Kettering Cancer Center.

The collaborative study involving researchers from Weill Cornell, Memorial Sloan-Kettering Cancer Center (MSKCC) and City University of New York (CUNY) will be the first to test the hypothesis that chemotherapy affects specific brain structures, particularly the hippocampus and white matter.

Dr. Correa hopes the research leads to efforts to identify "neuroprotective agents" that may minimize or prevent chemotherapy-related cognitive dysfunction.

A second three-year study will investigate techniques to improve detection of Normal Pressure Hydrocephalus (NPH), a condition in which an excess of fluid compresses the brain, causing disturbances in gait, balance, control of urination and memory.

This investigation will be led by Dr. Norman Relkin, an authority in the diagnosis of the condition and author of international guidelines for the diagnosis of NPH. He is director of the Memory Disorders Program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and associate professor of clinical neurology and neuroscience at Weill Cornell Medical College.

"NPH is treatable, but grossly under-recognized. Sadly, its symptoms are too often mistaken for Alzheimer's, Vascular Dementia or Parkinson's disease," explains Dr. Relkin. "There is currently no single method for objectively diagnosing NPH, and the available means of diagnosis involve a costly and time-consuming combination of clinical examinations, brain imaging and cerebrospinal fluid (CSF) drainage procedures. Furthermore, in published studies, the accuracy of this conventional approach is only about 50 percent in the hands of most physicians."

The three-year study will examine two techniques: Quantitative Diffusion Tensor Magnetic Resonance Imaging (QDT-MRI) and Proteomic Analysis of Cerebrospinal Fluid (PA-CSF) -- approaches Dr. Relkin says "have shown excellent promise in our preliminary study and could revolutionize NPH diagnosis and management."

Shelby White, founding trustee of the Leon Levy Foundation, says, "Leon was interested in the function of the human brain and its effects on behavior. He also had a very high regard for the work of Dr. Norman Relkin. This important research should advance our knowledge of these two perplexing neurological disorders. We have great confidence in the excellence of Dr. Relkin and Dr. Correa, and the NewYork-Presbyterian/Weill Cornell neurological program, and are therefore pleased to support this critical effort."


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
3. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
4. 1.5 million children could be saved
5. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
6. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
9. £5 million investment in personalized medicines to cut patient deaths
10. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently becoming ... require expert user knowledge. In a live webinar on April 11th and October ... highly accurate, determination of sodium. , It has long been known that too ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... ... has entered a settlement agreement to resolve the pending litigation between itself and ... for the District of Utah). , “I am thrilled to announce that we ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/27/2017)... ... , ... Harris Communications, Inc., a leading provider of assistive technology for ... Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in Houston. ... staff from Harris Communications and to try out the newest assistive devices available to ...
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for Garden Media ... All through the year, Garden Media aims to provide material helpful to clients’ goals ... pitching client’s key messages to gain coveted media placements, Garden Media wows ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Therapix Biosciences Ltd. (NASDAQ: ... the development of cannabinoid-based drugs, today announced the ... the United States of 2,000,000 American ... shares of the Company, at a price of ... the underwriters a 45-day over-allotment option to purchase ...
(Date:3/27/2017)... March 27, 2017  A recent study at Shriners ... freestanding hospitals in the country dedicated to the treatment ... surgery, concluded that the Surfacide Helios ® UV-C ... in reducing bacterial pathogens not killed by the EVS ... at the American Burn Association,s 49th Annual Meeting in ...
(Date:3/27/2017)... March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an ... passed early toxicology and efficacy studies. The company is ... a specific protein, MAGE A, in an effort to ... After 4 weeks of treatment in ... very little toxicity in a full toxicology report of ...
Breaking Medicine Technology: